3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Cisplatin
416
Radiotherapy
240
Radiotherapy, Intensity-Modulated
178
Cetuximab
177
Docetaxel
166
pembrolizumab
148
Carboplatin
121
Fluorouracil
113
Paclitaxel
90
Nivolumab
82
Gemcitabine
82
Radiation
72
Surveys and Questionnaires
71
Drug Therapy
70
toripalimab
68
Surgical Procedures, Operative
64
Magnetic Resonance Spectroscopy
63
Capecitabine
50
Blood Specimen Collection
50
Chemoradiotherapy
46
Biopsy
44
camrelizumab
41
durvalumab
40
Radiosurgery
40
Standard of Care
38
Erlotinib Hydrochloride
34
nimotuzumab
32
130-nm albumin-bound paclitaxel
32
tislelizumab
31
apatinib
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
etelcalcetide hydrochloride
×
Head & Neck
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts